Maya Eiger-Moscovich

Dr. Maya Eiger-Moscovich

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
MEMaya Eiger-Moscovich
Maya Eiger-Moscovich
EREhud Reich
Ehud Reich
GTGil Tauber
Gil Tauber
OBOri Berliner
Ori Berliner
APAyelet Priel
Ayelet Priel
IYIftach Yassur
Iftach Yassur

8 January 2016 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
MEMaya Eiger-Moscovich
Maya Eiger-Moscovich
RARadgonde Amer
Radgonde Amer
MOMerih Oray
Merih Oray
KTKhalid F. Tabbara
Khalid F. Tabbara
ITIlknur Tugal‐Tutkun
Ilknur Tugal‐Tutkun
MKMichal Kramer
Michal Kramer

3 February 2017 in Current Eye Research
Verified
Journal Article
Closed access
MEMaya Eiger-Moscovich
Maya Eiger-Moscovich
AGAssaf Gershoni
Assaf Gershoni
RARuth Axer-Siegel
Ruth Axer-Siegel
DWDov Weinberger
Dov Weinberger
RERita Ehrlich
Rita Ehrlich
Purpose: To study the efficacy and outcomes of short-term postoperative vitreoretinal tamponade with perfluorocarbon heavy liquid in patients with giant retinal tear. Materials and Methods: The study group consisted of 13 consecutive patients (13 eyes) who presented with giant retinal tear at a tertiary medical center in 2011–2015 and were treated with vitrectomy followed by short-term tamponade with perfluorocarbon heavy liquid. A minimum of 3 months’ follow-up was required for inclusion. The medical charts were retrospectively reviewed for patient demographics, procedural specifics, anatomical attachment rates, pre- and postoperative visual acuity, and postoperative complications. Results: The duration of perfluorocarbon tamponade ranged from 6 to 13 days (mean ± SD 10 ± 2 days). Follow-up time ranged from 3 to 44 months (mean ± SD 11 ± 11 months). Retinal reattachment was achieved intraoperatively in all patients. Repeated detachment with proliferative vitreoretinopathy occurred in one patient (8%), who underwent repeated vitrectomies. At the last follow-up visit, the retina was attached in all patients. Best-corrected visual acuity improved postoperatively compared with preoperatively in all three patients with macula-off retinal detachment (100%) and was equal to or better than the initial best-corrected visual acuity in 6 (60%) of the 10 patients with macula-on retinal detachment. Complications included increased intraocular pressure, cataract, and cystoid macular edema. Conclusions: Perfluorocarbon heavy liquid is a safe and effective material for short-term vitreoretinal tamponade following vitrectomy for giant retinal tear.

15 January 2020 in Ocular Oncology and Pathology
Verified
Journal Article
Open access
PDF file
MEMaya Eiger-Moscovich
Maya Eiger-Moscovich
RJRalph C. Eagle Jr.
Ralph C. Eagle Jr.
Carol ShieldsCarol Shields
Carol Shields
HRHilary Racher
Hilary Racher
SLSara E. Lally
Sara E. Lally
TMTatyana Milman
Tatyana Milman
Background: Muir-Torre syndrome (MTS) is defined clinically as the association of cutaneous sebaceous neoplasm and visceral malignancy. Ancillary tests are considered crucial for diagnosis. Although screening guidelines for MTS, including the Mayo MTS scoring system, have been proposed, there are no ophthalmic site-specific guidelines. Summary: A literature review conducted by PubMed search for articles describing patients with periocular sebaceous neoplasm and MTS disclosed 31 publications describing 60 patients, 36 (60%) of whom fulfilled clinical criteria for MTS, 6 (10%) whose diagnosis was based on screening ancillary studies, 14 (23%) who fulfilled clinical criteria and had supporting screening ancillary studies, and 4 (7%) who fulfilled clinical criteria and had supporting diagnostic genetic testing. Most patients were male (34 vs. 15 females), with a median age of 59 years (range 37–79 years). The most common diagnosis was sebaceous carcinoma (40/60, 67%), followed by sebaceous adenoma (16/60, 27%), followed by other tumors with sebaceous differentiation (4/60, 6%). The periocular lesions were identified prior to visceral malignancy in 10 out of 45 (22%) cases, after visceral malignancy in 34 out of 45 (76%) cases, and concurrently with visceral malignancy in 1 out of 45 (2%) cases. Immunohistochemistry for mismatch repair proteins was performed in 41 out of 60 (68%) and 14 out of 38 (37%) of the tumors had lost MSH2. Based on Mayo-MTS scores of 2 or greater, and after removing visceral malignancies not included in their scoring algorithm, 26 out of 30 of patients (87%) with complete data were considered to be appropriate candidates for further work-up. A survey of current practice was conducted by questionnaires, distributed to ophthalmic pathologists, ocular oncologists, and oculoplastic surgeons from national and international professional societies. Of the 103 physicians who participated in the survey, 91 (88%) felt that MTS evaluation guidelines were not sufficiently clear. Key Messages: Our findings suggest that Mayo MTS screening guidelines may be applicable to periocular sebaceous neoplasms. The uncertainty of ophthalmic specialists about optimal screening guidelines for MTS reflects the heterogeneity of defining criteria for MTS and limited molecular genetic data. Larger studies with detailed clinical, histopathologic, and molecular genetic data are required to formally assess screening guidelines for MTS in patients with periocular sebaceous neoplasms.

1 June 2019 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
MEMaya Eiger-Moscovich
Maya Eiger-Moscovich
ONOren Tomkins Netzer
Oren Tomkins Netzer
RARadgonde Amer
Radgonde Amer
ZHZohar Habot-Wilner
Zohar Habot-Wilner
AKAhmed Kasb
Ahmed Kasb
MKMichal Kramer
Michal Kramer

21 May 2019 in Ophthalmic Research
Verified
Journal Article
Open access
PDF file
MEMaya Eiger-Moscovich
Maya Eiger-Moscovich
ELEitan Livny
Eitan Livny
RSRuti Sella
Ruti Sella
OGOrly Gal-Or
Orly Gal-Or
YNYael Nisgav
Yael Nisgav
IBIrit Bahar
Irit Bahar
Aim: To compare the efficacy of aflibercept (Eylea®), a potent antivascular endothelial growth factor (VEGF) agent, with betamethasone (Celestone®) and placebo for the treatment of formed corneal neovascularization in a rabbit model. Methods: A central corneal chemical burn was created in the right eye of 24 New Zealand albino rabbits. Four weeks later, the rabbits were randomly divided into 4 equal groups for subconjunctival injection of aflibercept, betamethasone, aflibercept+ betamethasone, or saline (control). Digital photographs taken at weekly intervals were rated by 2 masked observers for extent, centricity, and density of corneal neovascularization according to a predefined scale. The percentage of corneal surface involved by neovascularization was quantified by image analysis software (Fiji-J). The change in corneal neovascularization from treatment administration (4 weeks after injury) to 4 weeks later (8 weeks after injury) was assessed. The rabbits were then euthanized, and their eyes were enucleated and processed for histopathological and immunofluorescence studies. Results: There was no significant difference in the change in corneal neovascularization after treatment among the 4 groups according to the digital images (p > 0.15) or histological evaluation with hematoxylin and eosin (p > 0.08). On immunofluorescence assay, a lower VEGF concentration was observed in all treatment groups compared to the control group. Conclusions: In this rabbit model, corneal neovascularization induced by chemical burn failed to regress with treatment with aflibercept, betamethasone, or their combination.